IONS Q3 2019 Earnings — Ionis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IONSIonis Pharmaceuticals, Inc.

$12B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$168M+15.5% YoY

Gross Profit

$167M99.4% margin

Operating Income

$3M1.5% margin

Net Income

$26M15.6% margin

EPS (Diluted)

$0.18

QoQ Revenue Growth

+2.5%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$31M

Stock-Based Comp.

$24M

Balance Sheet

Total Assets

$2.9B

Total Liabilities

$1.4B

Stockholders' Equity

$1.3B

Cash & Equivalents

$248M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$168M	$145M	+15.5%
Gross Profit	$167M	$145M	+14.8%
Operating Income	$3M	-$19M	+113.6%
Net Income	$26M	-$5M	+673.9%

Revenue Segments

Commercial

$96M36%

SPINRAZA Royalties

$82M31%

Research and Development Revenue Under Collaborative Agreements

$72M27%

Product

$12M5%

Licensing and Other Royalties

$2M1%